WO2007147529A2 - Recombinant viral vaccine - Google Patents
Recombinant viral vaccine Download PDFInfo
- Publication number
- WO2007147529A2 WO2007147529A2 PCT/EP2007/005303 EP2007005303W WO2007147529A2 WO 2007147529 A2 WO2007147529 A2 WO 2007147529A2 EP 2007005303 W EP2007005303 W EP 2007005303W WO 2007147529 A2 WO2007147529 A2 WO 2007147529A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- branched
- straight
- moiety
- group
- phenyl
- Prior art date
Links
- 229960004854 viral vaccine Drugs 0.000 title claims abstract description 50
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 239000013603 viral vector Substances 0.000 claims abstract description 43
- 238000001727 in vivo Methods 0.000 claims abstract description 14
- 239000000427 antigen Substances 0.000 claims description 81
- 108091007433 antigens Proteins 0.000 claims description 81
- 102000036639 antigens Human genes 0.000 claims description 81
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 48
- -1 (phenyl) ethyl Chemical group 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000004432 carbon atom Chemical group C* 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 37
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 28
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Chemical group 0.000 claims description 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 54
- 102000004196 processed proteins & peptides Human genes 0.000 description 50
- 238000000034 method Methods 0.000 description 39
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 38
- 229920001184 polypeptide Polymers 0.000 description 38
- 206010028980 Neoplasm Diseases 0.000 description 34
- 239000000203 mixture Substances 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 26
- 230000003612 virological effect Effects 0.000 description 26
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- 239000013598 vector Substances 0.000 description 22
- 241000700605 Viruses Species 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- WUUCVVFSWNXYRD-UHFFFAOYSA-N chembl19191 Chemical class C1=CC=C2C3=NC=NC3=C(N)NC2=C1 WUUCVVFSWNXYRD-UHFFFAOYSA-N 0.000 description 16
- 230000003248 secreting effect Effects 0.000 description 16
- 229960002751 imiquimod Drugs 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000012384 transportation and delivery Methods 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229920000136 polysorbate Polymers 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 241000700618 Vaccinia virus Species 0.000 description 8
- 238000004873 anchoring Methods 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000011200 topical administration Methods 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 229940060265 aldara Drugs 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- WSIZDLIFQIDDKA-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinolin-2-amine Chemical class C1=CC=NC2=C(NC(N)=N3)C3=CC=C21 WSIZDLIFQIDDKA-UHFFFAOYSA-N 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 238000011510 Elispot assay Methods 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000008348 humoral response Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 208000031504 Asymptomatic Infections Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000028996 humoral immune response Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000003607 modifier Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000010735 Adenomatous polyposis coli protein Human genes 0.000 description 3
- 108010038310 Adenomatous polyposis coli protein Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 206010008263 Cervical dysplasia Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- 102100034353 Integrase Human genes 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 108010078428 env Gene Products Proteins 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- ZAPSNGHNEPUZEG-UHFFFAOYSA-N 1-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(C)=N3)CC(C)(C)O)C3=C(N)N=C21 ZAPSNGHNEPUZEG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000219496 Alnus Species 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 244000281762 Chenopodium ambrosioides Species 0.000 description 2
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 2
- 235000005490 Chenopodium botrys Nutrition 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 240000005109 Cryptomeria japonica Species 0.000 description 2
- 241000723198 Cupressus Species 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100040578 G antigen 7 Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 2
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101100232904 Homo sapiens IL2 gene Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000721662 Juniperus Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000795633 Olea <sea slug> Species 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 231100001222 nononcogenic Toxicity 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- CNBOKXFMODKQCT-UHFFFAOYSA-N 1-(4-aminoimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C3N(CC(C)(O)C)C=NC3=C(N)N=C21 CNBOKXFMODKQCT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 102100021879 Adenylyl cyclase-associated protein 2 Human genes 0.000 description 1
- 101710137132 Adenylyl cyclase-associated protein 2 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000209136 Agropyron Species 0.000 description 1
- 241000743339 Agrostis Species 0.000 description 1
- 240000005611 Agrostis gigantea Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 241000743857 Anthoxanthum Species 0.000 description 1
- 240000004178 Anthoxanthum odoratum Species 0.000 description 1
- 235000014251 Anthoxanthum odoratum Nutrition 0.000 description 1
- 101100504181 Arabidopsis thaliana GCS1 gene Proteins 0.000 description 1
- 241000508787 Arrhenatherum Species 0.000 description 1
- 241000508786 Arrhenatherum elatius Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 101000874387 Astacus leptodactylus Sarcoplasmic calcium-binding protein 1 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 241000219429 Betula Species 0.000 description 1
- 235000003932 Betula Nutrition 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241000238658 Blattella Species 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000209200 Bromus Species 0.000 description 1
- 241000743756 Bromus inermis Species 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100455063 Caenorhabditis elegans lmp-1 gene Proteins 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000723437 Chamaecyparis Species 0.000 description 1
- 241000723436 Chamaecyparis obtusa Species 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000209210 Dactylis Species 0.000 description 1
- 240000004585 Dactylis glomerata Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 241000234645 Festuca pratensis Species 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 102100039699 G antigen 4 Human genes 0.000 description 1
- 102100039698 G antigen 5 Human genes 0.000 description 1
- 101710092267 G antigen 5 Proteins 0.000 description 1
- 102100039713 G antigen 6 Human genes 0.000 description 1
- 101710092269 G antigen 6 Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000040452 GAGE family Human genes 0.000 description 1
- 108091072337 GAGE family Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101710091881 GTPase HRas Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100030525 Gap junction alpha-4 protein Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000226709 Hesperocyparis arizonica Species 0.000 description 1
- 241000744855 Holcus Species 0.000 description 1
- 240000003857 Holcus lanatus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000886678 Homo sapiens G antigen 2D Proteins 0.000 description 1
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 1
- 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 1
- 101001114057 Homo sapiens P antigen family member 1 Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000721668 Juniperus ashei Species 0.000 description 1
- 241000592238 Juniperus communis Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 244000100545 Lolium multiflorum Species 0.000 description 1
- 240000004296 Lolium perenne Species 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 1
- 102100027248 Melanoma-associated antigen C3 Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100232925 Mus musculus Il4 gene Proteins 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100023219 P antigen family member 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241001465379 Parietaria judaica Species 0.000 description 1
- 241000721464 Parietaria officinalis Species 0.000 description 1
- 241001330453 Paspalum Species 0.000 description 1
- 241001330451 Paspalum notatum Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 1
- 241000238661 Periplaneta Species 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 241000745991 Phalaris Species 0.000 description 1
- 244000081757 Phalaris arundinacea Species 0.000 description 1
- 241000746981 Phleum Species 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 241000209048 Poa Species 0.000 description 1
- 241000136254 Poa compressa Species 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 244000274906 Quercus alba Species 0.000 description 1
- 235000009137 Quercus alba Nutrition 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 244000004774 Sabina virginiana Species 0.000 description 1
- 235000008691 Sabina virginiana Nutrition 0.000 description 1
- 101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 244000082988 Secale cereale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 101710134694 Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 101100060882 Yersinia pestis pla gene Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 108010015408 connexin 37 Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 108010048032 cyclophilin B Proteins 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 108010006620 fodrin Proteins 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 102000054078 gamma Catenin Human genes 0.000 description 1
- 108010084448 gamma Catenin Proteins 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000011488 interferon-alpha production Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 102200015251 rs148489044 Human genes 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention provides new recombinant viral vaccines.
- the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors.
- Live vaccines are typically attenuated non-pathogenic versions of an infectious agent that are capable of priming an immune response directed against a pathogenic version of the infectious agent.
- recombinant vaccines especially recombinant live vaccines, in which foreign antigens of interest are encoded and expressed from a vector.
- vectors based on recombinant viruses have shown great promise and play an important role in the development of new vaccines.
- viruses have been investigated for their ability to express proteins from foreign pathogens or tumoral tissue, and to induce specific immunological responses against these antigens in vivo.
- these gene-based vaccines can stimulate potent humoral and cellular immune responses and viral vectors might be an effective strategy for both the delivery of antigen- encoding genes and the facilitation and enhancement of antigen presentation.
- the ideal viral vector In order to be utilized as a vaccine carrier, the ideal viral vector should be safe and enable efficient presentation of required pathogen-specific antigens to the immune system. It should also exhibit low intrinsic immunogenicity to allow for its re-administration in order to boost relevant specific immune responses.
- the vector system must meet criteria that enable its production on a large-scale basis.
- Recombinant poxvirus vectors are examples of viral vaccine vectors. They have been used as inducers of both humoral and cellular immune responses, inducing both CD4+ and CD8+ T cells, and therefore represent a delivery system of choice especially in cancer or antiviral immunotherapy (see Arlen et al., 2005, Semin Oncol. , 32, 549-555 or Essajee and Kaufman , 2004, Expert Opin Biol Ther., 4, 575-588).
- IRMs immune response modifiers
- TLRs Toll-like receptors
- cytokines biosynthesis e.g., interferons, interleukins, tumor necrosis factor, etc.
- IRMs immunostimulating responses induced by IRMs
- IFN- alpha production is believed to be very important in the acute antiviral and antitumor activities seen.
- up regulation of other cytokines such as, for example, tumor necrosis factor (TNF) , IL-I and IL-6 also have potentially beneficial activities and are believed to contribute to the antiviral and antitumor properties of these compounds.
- Immune response modifiers have been disclosed as useful for treating a wide variety of diseases and conditions, including viral diseases (e.g., human papilloma virus, hepatitis, herpes), neoplasias (e.g., basal cell carcinoma, squamous cell carcinoma, actinic keratosis, melanoma) , and TH2- mediated diseases (e.g., asthma, allergic rhinitis, atopic dermatitis).
- viral diseases e.g., human papilloma virus, hepatitis, herpes
- neoplasias e.g., basal cell carcinoma, squamous cell carcinoma, actinic keratosis, melanoma
- TH2- mediated diseases e.g., asthma, allergic rhinitis, atopic dermatitis.
- IRMs immune response modifiers
- CpG oligonucleotides see US 6,194,388; US2006094683; WO 2004039829 for example
- lipopolysaccharides see US 6,194,388; US2006094683; WO 2004039829 for example
- lipopolysaccharides see US 6,194,388; US2006094683; WO 2004039829 for example
- lipopolysaccharides e.g., lipopolysaccharides
- polyinosicrpolycytidylic acid complexes see WO 2004039829
- polyinosicrpolycytidylic acid complexes see US 6,194,388; US2006094683; WO 2004039829 for example
- lipopolysaccharides see US 6,194,388; US2006094683; WO 2004039829 for example
- lipopolysaccharides see US 6,194,388; US2006094683
- IRMs immune response modifiers
- small organic molecule such as imidazoquinolinamines, imidazopyridine amines, 6,7- fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines and 1,2-bridged imidazoquinoline amines (see for example US 4,689,338; US 5,389,640; US 6,110,929; and US 6,331,539).
- the imidazoquinolinamines have demonstrated strong potency as inducers of interferon-alpha (IFN), tumor necrosis factor-alpha (TNF), interleukin IL-I beta, IL-6, IL-I alpha, IL-I receptor antagonist, IL-10, granulocyte-macrophage colony-stimulating factor (GM-CSF) , granulocyte CSF (G-CSF) , and macrophage inflammatory protein-1 alpha in vitro and in vivo (Gibson et al., 1995, J Interferon Cytokine Res. ,15, 537-545 ; Tomai et al., 1995, Antiviral Res.
- IFN interferon-alpha
- TNF tumor necrosis factor-alpha
- TNF tumor necrosis factor-alpha
- IL-I beta interleukin IL-I beta
- IL-6 interleukin IL-I beta
- IL-6 interleukin IL-I
- imidazoquinolinamines were able to enhance the immune response towards certain antigens such as live viral and bacterial immunogens, tumor- derived, protozoal, organism-derived, fungal and bacterial immunogens, toxoids, toxins, polysaccharides, proteins, glycoproteins, peptides and the like when these antigens were co-administered with this category of compounds.
- imidazoquinolinamine compounds have been further demonstrated against a variety of viruses, especially poxviruses (Bikowski, 2004, Cutis., 73, 202-206 ; US 20050048072), and their clinical efficacy has been demonstrated against genital warts (Scheinfeld and Lehman, 2006, Dermatol Online J., 12, 5), herpes genitalis (Miller et al, 2002, Int Immunopharmacol . , 2, 443-451) and molluscum contagiosum (Stulberg and Galbraith Hutchinson, 2003, Am. Fam. Physician, 67, 1233-1240) .
- the present invention relates to an improvement to recombinant viral vaccines expressing in vivo at least one heterologous nucleotide sequence, especially a nucleotide sequence encoding an antigen. It relates in particular to a recombinant viral vaccine containing at least one recombinant viral vector expressing at least one • antigen and at least one adjuvant which is capable of remarkably increasing the immunity conferred against said antigen relative to the same recombinant viral vaccine with no adjuvant and which is perfectly suitable for this type of vaccine. It further relates to vaccination methods relating thereto.
- the subject of the present invention is therefore a recombinant viral vaccine containing (i) at least one recombinant viral vector expressing in vivo at least one heterologous nucleotide sequence, especially an heterologous nucleotide sequence encoding an antigen, and (ii) at least one IH-imidazo [4 , 5-c] quinolin-4-amine derivative.
- said lH-imidazo [4, 5-c] quinolin-4-amine derivative enhances the immune responses in a patient to the said antigen where the said recombinant viral vaccine is administered to said patient .
- a and “an” are used in the sense that they mean “at least one”, “at least a first”, “one or more” or “a plurality” of the referenced compounds or steps, unless the context dictates otherwise.
- a cell includes a plurality of cells including a mixture thereof. More specifically, “at least one” and “one or more” means a number which is one or greater than one, with a special preference for one, two or three.
- patient refers to a vertebrate, particularly a member of the mammalian species and includes, but is not limited to, domestic animals, sport animals, primates including humans.
- patient is in no way limited to a special disease status, it encompasses both patients who have already developed a disease of interest and patients who are not sick.
- treatment or “treating” encompasses prophylaxis and/or therapy. Accordingly the recombinant viral vaccines of the present invention are not limited to therapeutic applications and can be used in prophylaxis ones.
- the recombinant viral vector according to the present invention is a poxviral vector (see for example Cox et al. in "Viruses in Human Gene Therapy” Ed J. M. Hos, Carolina Academic Press) .
- poxviral vector see for example Cox et al. in "Viruses in Human Gene Therapy” Ed J. M. Hos, Carolina Academic Press
- suitable vaccinia viruses include without limitation the Copenhagen strain (Goebel et al., 1990, Virol. 179, 247-266 and 517-563; Johnson et al . , 1993, Virol.
- the Wyeth strain and the highly attenuated attenuated virus derived thereof including MVA (for review see Mayr, A., et al., 1975, Infection 3, 6-14) and derivates thereof (such as MVA vaccinia strain 575 (ECACC V00120707 - US 6,913,752), NYVAC (see WO 92/15672 - Tartaglia et al., 1992, Virology, 188, 217-232). It may also be obtained from any other member of the poxviridae, in particular fowlpox (e.g.
- TROVAC see Paoletti et al, 1995, Dev Biol Stand., 84, 159-163); canarypox (e.g. ALVAC, WO 95/27780, Paoletti et al, 1995, Dev Biol Stand., 84, 159-163); pigeonpox; swinepox and the like.
- canarypox e.g. ALVAC, WO 95/27780, Paoletti et al, 1995, Dev Biol Stand., 84, 159-163
- pigeonpox swinepox and the like.
- persons skilled in the art may refer to WO 92 15672 (incorporated by reference) which describes the production of expression vectors based on poxviruses capable of expressing such heterologous nucleotide sequence, especially nucleotide sequence encoding antigen.
- antigen refers to any substance that is capable of being the target of an immune response.
- An antigen may be the target of, for example, a cell-mediated and/or humoral immune response raised by a patient.
- the term "antigen” encompasses for example viral antigens, tumour-specific or -related antigens, bacterial antigens, parasitic antigens, allergens and the like :
- Viral antigens include for example antigens from hepatitis viruses A, B, C, D & E, HIV, herpes viruses, cytomegalovirus, varicella zoster, papilloma viruses, Epstein Barr virus, influenza viruses, para-influenza viruses, adenoviruses, coxsakie viruses, picorna viruses, rotaviruses, respiratory syncytial viruses, pox viruses, rhinoviruses, rubella virus, papovirus, mumps virus, measles virus; some non-limiting examples of known viral antigens include the following : antigens derived from HIV-I such as tat, nef, gpl20 or gpl ⁇ O, gp40, p24, gag, env, vif, vpr, vpu, rev or part and/or combinations thereof; antigens derived from human herpes viruses such as gH, gL gM gB gC
- env protein El or E2 core protein, NS2, NS3, NS4a, NS4b, NS5a, NS5b, p7, or part and/or combinations thereof of HCV) ; antigens derived from human papilloma viruses (for example HPV6,11,16, 18, e.g. Ll, L2, El, E2, E3, E4, E5, E6, E7, or part and/or combinations thereof) ; antigens derived from other viral pathogens, such as Respiratory Syncytial virus (e.g F and G proteins or derivatives thereof), parainfluenza virus, measles virus, mumps virus, flaviviruses (e. g.
- tumor-specific or -related antigens includes for example antigens from breast cancer, colon cancer, rectal cancer, cancer of the head and neck, renal cancer, malignant melanoma, laryngeal cancer, ovarian cancer, cervical cancer, prostate cancer.
- Cancer antigens are antigens which can potentially stimulate apparently tumor-specific immune responses. Some of these antigens are encoded, although not necessarily expressed, by normal cells.
- cancer antigens can be characterized as those which are normally silent (i.e., not expressed) in normal cells, those that are expressed only at certain stages of differentiation and those that are temporally expressed such as embryonic and fetal antigens.
- Other cancer antigens are encoded by mutant cellular genes, such as oncogenes (e.g., activated ras oncogene), suppressor genes (e.g., mutant p53) , fusion proteins resulting from internal deletions or chromosomal translocations.
- Still other cancer antigens can be encoded by viral genes such as those carried on RNA and DNA tumor viruses.
- tumor-specific or -related antigens include MART- 1/Melan-A, gplOO, Dipeptidyl peptidase IV (DPPIV) , adenosine deaminase-binding protein (ADAbp) , cyclophilin b, Colorectal associated antigen (CRC) -C017-1A/GA733, Carcinoembryonic Antigen (CEA) and its immunogenic epitopes CAP-I and CAP-2, etv ⁇ , amll, Prostate Specific Antigen (PSA) and its immunogenic epitopes PSA-I, PSA-2, and PSA-3, prostate- specific membrane antigen (PSMA), T-cell receptor/CD3-zeta chain, MAGE-family of tumor antigens (e.g., MAGE-Al, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-
- MUC-I MUC-I
- HER2/neu p21ras
- RCASl alpha-fetoprotein
- E-cadherin alpha-catenin
- beta- catenin alpha-catenin
- gamma-catenin pl20ctn, gplOO . sup .
- - bacterial antigens includes for example antigens from Mycobacteria causing TB and leprosy, pneumocci, aerobic gram negative bacilli, mycoplasma, staphyloccocal infections, streptococcal infections, salmonellae, chlamydiae, neisseriae; other antigens includes for example antigens from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis, schistosomiasis, filariasis; allergens refer to a substance that can induce an allergic or asthmatic response in a susceptible subject.
- allergens can include pollens, insect venoms, animal dander dust, fungal spores and drugs (e.g. penicillin) .
- natural, animal and plant allergens include but are not limited to proteins specific to the following genuses: Canine (Canis familiaris) ; Dermatophagoides (e.g. Dermatophagoides farinae) ; Felis (Felis domesticus) ; Ambrosia (Ambrosia artemiisfolia; Lolium (e.g.
- Lolium perenne or Lolium multiflorum Lolium perenne or Lolium multiflorum
- Cryptomeria Cerptomeria japonica
- Alternaria Alternaria alternata
- Alder Alnus
- Alnus gultinoasa Betula
- Betula Betula verrucosa
- Quercus Quercus alba
- Olea Olea
- Artemisia Artemisia vulgaris
- Plantago e.g. Plantago lanceolata
- Parietaria e.g.
- Juniperus e.g. Juniperus sabinoides
- Thuya e.g. Thuya orientalis
- Chamaecyparis e.g.
- Triticum e.g. Triticum aestivum
- Dactylis e.g. Dactylis
- Anthoxanthum e.g.
- Anthoxanthum odoratum ; Arrhenatherum (e.g. Arrhenatherum elatius); Agrostis (e.g. Agrostis alba); Phleum (e.g. Phleum pratense) ; Phalaris (e.g. Phalaris arundinacea) ; Paspalum
- Sorghum e.g. Sorghum halepensis
- Bromus e.g. Bromus inermis
- the heterologous nucleotide sequence of the present invention encodes one or more of all or part of the following antigens HBV-PreSl PreS2 and Surface env proteins, core and polHIV- gpl20 gp40,gpl60, p24, gag, pol, env, vif, vpr, vpu, tat, rev, nef; HPV-El, E2, E3, E4, E5, E6, E7, E8, Ll, L2 (see for example WO 90/10459, WO 98/04705, WO 99/03885); HCV env protein El or E2, core protein, NS2, NS3, NS4a, NS4b, NS5a, NS5b, p7; Muc-1 (see for example US 5,861,381; US6,054,438; WO98/04727; WO98/37095) .
- the nucleic acid encoding the antigen is operatively linked to a gene expression sequence which directs the expression of the antigen nucleic acid within a eukaryotic cell .
- the gene expression sequence is any regulatory nucleotide sequence, such as a promoter sequence or promoter- enhancer combination, which facilitates the efficient transcription and translation of the antigen nucleic acid to which it is operatively linked.
- the gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter.
- Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPRT) , adenosine deaminase, pyruvate kinase, b-actin promoter and other constitutive promoters.
- HPRT hypoxanthine phosphoribosyl transferase
- Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the cytomegalovirus (CMV) , simian virus (e.g., SV40) , papilloma virus, adenovirus, human immunodeficiency virus (HIV) , Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of Moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus.
- CMV cytomegalovirus
- simian virus e.g., SV40
- papilloma virus e.g., SV40
- HSV40 human immunodeficiency virus
- HSV40 human immunodeficiency virus
- Rous sarcoma virus Rous sarcoma virus
- cytomegalovirus cytomegalovirus
- LTR long terminal repeats
- Inducible promoters are expressed in the presence of an inducing agent.
- the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions .
- Other inducible promoters are known to those of ordinary skill in the art.
- the gene expression sequence shall include, as necessary, 5 1 non-transcribing and 5 1 non- translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like.
- 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined antigen nucleic acid.
- the gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.
- Preferred promoters for use in a poxviral vector include without limitation vaccinia promoters 7.5K, H5R, TK, p28, pll and KlL, chimeric promoters between early and late poxviral promoters as well as synthetic promoters such as those described in Chakrabarti et al . (1997, Biotechniques 23, 1094-1097), Hammond et al. (1997, J. Virological Methods 66, 135-138) and Kumar and Boyle (1990, Virology 179, 151-158).
- said heterologous nucleotide sequence of the present invention encodes all or part of HPV antigen (s) selected in the group consisting of E6 early coding region of HPV, E7 early coding region of HPV and derivates or combination thereof.
- the HPV antigen encoded by the recombinant viral vector according to the invention is selected in the group consisting of an HPV E6 polypeptide, an HPV E7 polypeptide or both an HPV E6 polypeptide and an HPV E7 polypeptide.
- the present invention encompasses the use of any HPV E ⁇ polypeptide which binding to p53 is altered or at least significantly reduced and/or the use of any HPV E7 polypeptide which binding to Rb is altered or at least significantly reduced (Munger et al., 1989, EMBO J. 8, 4099-4105; Crook et al . , 1991, Cell 67, 547- 556; Heck et al., 1992, Proc . Natl. Acad. Sci.
- a non- oncogenic HPV-16 E6 variant which is suitable for the purpose of the present invention is deleted of one or more amino acid residues located from approximately position 118 to approximately position 122 (+1 representing the first methionine residue of the native HPV-16 E6 polypeptide) , with a special preference for the complete deletion of residues 118 to 122 (CPEEK) .
- HPV-16 E7 variant which is suitable for the purpose of the present invention is deleted of one or more amino acid residues located from approximately position 21 to approximately position 26 (+1 representing the first amino acid of the native HPV-16 E7 polypeptide, with a special preference for the complete deletion of residues 21 to 26 (DLYCYE) .
- the one or more HPV-16 early polypeptide (s) in use in the invention is/are further modified so as to improve MHC class I and/or MHC class II presentation, and/or to stimulate anti-HPV immunity.
- HPV E6 and E7 polypeptides are nuclear proteins and it has been previously shown that membrane presentation permits to improve their therapeutic efficacy (see for example WO99/03885) .
- HPV early polypeptide s
- Membrane anchorage can be easily achieved by incorporating in the HPV early polypeptide a membrane- anchoring sequence and if the native polypeptide lacks it a secretory sequence (i.e. a signal peptide).
- a secretory sequence i.e. a signal peptide.
- Membrane-anchoring and secretory sequences are known in the art. Briefly, secretory sequences are present at the N-terminus of the membrane presented or secreted polypeptides and initiate their passage into the endoplasmic reticulum (ER) .
- Membrane-anchoring sequences are usually highly hydrophobic in nature and serves to anchor the polypeptides in the cell membrane (see for example Branden and Tooze, 1991, in Introduction to Protein Structure p. 202-214, NY Garland) .
- membrane-anchoring and secretory sequences which can be used in the context of the present invention is vast. They may be obtained from any membrane- anchored and/or secreted polypeptide comprising it (e.g. cellular or viral polypeptides) such as the rabies glycoprotein, of the HIV virus envelope glycoprotein or of the measles virus F protein or may be synthetic.
- the membrane anchoring and/or secretory sequences inserted in each of the early HPV-16 polypeptides used according to the invention may have a common or different origin.
- the preferred site of insertion of the secretory sequence is the N-terminus downstream of the codon for initiation of translation and that of the membrane-anchoring sequence is the C-terminus, for example immediately upstream of the stop codon.
- HPV E6 polypeptide in use in the present invention is preferably modified by insertion of the secretory and membrane-anchoring signals of the measles F protein.
- HPV E7 polypeptide in use in the present invention is preferably modified by insertion of the secretory and membrane-anchoring signals of the rabies glycoprotein.
- the therapeutic efficacy of the recombinant viral vector can also be improved by using one or more nucleic acid encoding immunopotentiator polypeptide (s) .
- a polypeptide such as calreticulin (Cheng et al . , 2001, J. Clin. Invest. 108, 669-678), Mycobacterium tuberculosis heat shock protein 70 (HSP70) (Chen et al., 2000, Cancer Res. 60, 1035- 1042 " ), ubiquitin (Rodriguez et al., 1997, J. Virol.
- the recombinant viral vector according to the invention comprises a nucleic acid encoding one or more early polypeptide (s) as above defined, and more particularly HPV-16 and/or HPV-18 early E6 and/or E7 polypeptides.
- said heterologous nucleotide sequence of the present invention encodes all or part of MUC 1 antigen or derivates thereof.
- the nucleic acid molecule in use in the invention may be optimized for providing high level expression of the antigen (e.g. HPV early polypeptide (s) ) in a particular host cell or organism, e.g. a human host cell or organism.
- codon optimisation is performed by replacing one or more "native" (e.g. HPV) codon corresponding to a codon infrequently used in the mammalian host cell by one or more codon encoding the same amino acid which is more frequently used. This can be achieved by conventional mutagenesis or by chemical synthetic techniques (e.g. resulting in a synthetic nucleic acid) . It is not necessary to replace all native codons corresponding to infrequently used codons since increased expression can be achieved even with partial replacement. Moreover, some deviations from strict adherence to optimised codon usage may be made to accommodate the introduction of restriction site(s).
- poxviral vector is preferred, and more specifically highly attenuated vaccinia virus strains. Determination of the complete sequence of the MVA genome and comparison with the Copenhagen vaccinia virus genome has allowed the precise identification of the seven deletions (I to VII) which occurred in the MVA genome (Antoine et al . , 1998, Virology 244, 365-396), any of which can be used to insert the antigen (e.g. HPV early polypeptide or MUCl) encoding nucleic acid.
- antigen e.g. HPV early polypeptide or MUCl
- the nucleic acid encoding the antigen of the Invention is preferably inserted in a nonessential locus of the poxviral genome, in order that the recombinant poxvirus remains viable and infectious.
- Nonessential regions are non-coding intergenic regions or any gene for which inactivation or deletion does not significantly impair viral growth, replication or infection.
- the antigen- encoding nucleic acid is preferably inserted in the thymidine kinase gene (tk) (Hruby et al . , 1983, Proc. Natl. Acad. Sci USA 80, 3411-3415; Weir et al., 1983, J. Virol. 46, 530-537).
- tk thymidine kinase gene
- other insertion sites are also appropriate, e.g. in the hemagglutinin gene (Guo et al . , 1989, J. Virol. 63, 4189- 4198), in the KlL locus, in the u gene (Zhou et al., 1990, J. Gen. Virol.
- the antigen-encoding nucleic acid can be inserted in anyone of the identified deletions I to VII as well as in the D4R locus, but insertion in deletion II or III is preferred (Meyer et al., 1991, J. Gen. Virol. 72, 1031-1038 ; Sutter et al., 1994, Vaccine 12, 1032-1040).
- the antigen-encoding nucleic acid is preferably introduced in the intergenic region situated between ORFs 7 and 9 (see for example EP 314 569 and US 5,180, 675) .
- the antigen-encoding nucleic acid in use in the invention is in a form suitable for its expression in a host cell or organism, which means that the nucleic acid sequence encoding the antigen (e.g. E6 polypeptide and/or the nucleic acid sequence encoding the E7 polypeptide) are placed under the control of one or more regulatory sequences necessary for expression in the host cell or organism.
- regulatory sequence refers to any sequence that allows, contributes or modulates the expression of a nucleic acid in a given host cell, including replication, duplication, transcription, splicing, translation, stability and/or transport of the nucleic acid or one of its derivative (i.e. mRNA) into the host cell. It will be appreciated by those skilled in the art that the choice of the regulatory sequences can depend on factors such as the host cell, the vector and the level of expression desired.
- the promoter is of special importance and the present invention encompasses the use of constitutive promoters which direct expression of the nucleic acid in many types of host cell and those which direct expression only in certain host cells or in response to specific events or exogenous factors (e.g. by temperature, nutrient additive, hormone or other ligand) .
- Suitable promoters are widely described in literature and one may cite more specifically viral promoters such as RSV, SV40, CMV and MLP promoters.
- Preferred promoters for use in a poxviral vector include without limitation vaccinia promoters 7.5K, H5R, TK, p28, pll and KlL, chimeric promoters between early and late poxviral promoters as well as synthetic promoters such as those described in Chakrabarti et al. (1997, Biotechniques 23, 1094-1097), Hammond et al . (1997, J. Virological Methods 66, 135-138) and Kumar and Boyle (1990, Virology 179, 151-158) .
- the regulatory elements controlling the expression of the nucleic acid molecule of the invention may further comprise additional elements for proper initiation, regulation and/or termination of transcription (e.g. polyA transcription termination sequences), mRNA transport (e.g. nuclear localization signal sequences), processing (e.g. splicing signals), and stability (e.g. introns and non-coding 5' and 3 1 sequences), translation (e.g. peptide signal, propeptide, tripartite leader sequences, ribosome binding sites, Shine-Dalgamo sequences, etc.) into the host cell or organism.
- transcription e.g. polyA transcription termination sequences
- mRNA transport e.g. nuclear localization signal sequences
- processing e.g. splicing signals
- stability e.g. introns and non-coding 5' and 3 1 sequences
- translation e.g. peptide signal, propeptide, tripartite leader sequences, ribosome binding sites, Shine-Dalgamo sequences,
- the recombinant viral vector in use in the present invention can further comprise at least one nucleic acid encoding at least one cytokine.
- Suitable cytokines include without limitation IL-2, IL-7, IL-15, IL-18, IL-21 and IFNg, with a special preference for IL-2.
- the recombinant viral vaccine of the invention comprises a cytokine-expressing nucleic acid
- said nucleic acid may be carried by the recombinant viral vector encoding the one or more HPV early polypeptide (s) or by an independent recombinant vector which can be of the same or a different origin.
- a preferred embodiment of the invention is directed to the use of a recombinant viral vaccine comprising a MVA vector encoding the HPV E6 polypeptide placed under the 7.5K promoter, the HPV E7 polypeptide placed under the 7.5K promoter and the human IL-2 gene placed under the control of the H5R promoter.
- a recombinant viral vaccine comprising a MVA vector encoding the HPV E6 polypeptide placed under the 7.5K promoter, the HPV E7 polypeptide placed under the 7.5K promoter and the human IL-2 gene placed under the control of the H5R promoter.
- nucleic acids encoding the HPV E6 polypeptide, the HPV E7 polypeptide and the human IL-2 are inserted in deletion III of the MVA genome.
- Another preferred embodiment of the invention is directed to the use of a recombinant viral vaccine comprising a MVA vector encoding the MUC 1 polypeptide placed under the 7.5K promoter, and the human IL-2 gene placed under the control of the H5R promoter.
- Infectious viral particles comprising the above-described recombinant viral vector can be produced by routine process.
- An exemplary process comprises the steps of: a. introducing the viral vector into a suitable cell line, b. culturing said cell line under suitable conditions so as to allow the production of said infectious viral particle, c. recovering the produced infectious viral particle from the culture of said cell line, and d. optionally purifying said recovered infectious viral particle .
- Cells appropriate for propagating poxvirus vectors are avian cells, and most preferably primary chicken embryo fibroblasts (CEF) prepared from chicken embryos obtained from fertilized eggs.
- CEF primary chicken embryo fibroblasts
- the infectious viral particles may be recovered from the culture supernatant or from the cells after lysis (e.g. by chemical means, freezing/thawing, osmotic shock, mecanic shock, sonication and the like) .
- the viral particles can be isolated by consecutive rounds of plaque purification and then purified using the techniques of the art (chromatographic methods, ultracentrifugation on cesium chloride or sucrose gradient) .
- the lH-imidazo [4, 5- c] quinolin-4-amine-derivative of the present invention is a compound defined by one of the following general formulae I-V :
- Rn is selected from the group consisting of straight or branched alkyl, hydroxyalkyl, acyloxyalkyl, benzyl, (phenyl) ethyl and phenyl, said benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties selected, independently from one another, from the group consisting of Ci_ 4 alkyl moiety, Ci- 4 alkoxy moiety and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than 6 carbon atoms;
- R2i is selected from the group consisting of hydrogen, Ci- 8 alkyl moiety, benzyl, (phenyl) ethyl and phenyl, the benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene
- Ri 2 is selected from the group consisting of straight or branched C 2 - 10 alkenyl and substituted straight or branched C2-10 alkenyl, wherein the substituent is selected from the group consisting of straight or branched C1- 4 alkyl moiety and C 3 - 6 cycloalkyl moiety; and C 3 - 6 cycloalkyl moiety substituted by straight or branched C 1 - 4 alkyl moiety; and
- R 22 is selected from the group consisting of hydrogen, straight or branched Ci_ 8 alkyl moiety, benzyl, (phenyl) ethyl and phenyl, the benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties selected, independently from one another, from the group consisting of straight or branched C 1 - 4 alkyl moiety, straight or branched C 1 - 4 alkoxy moiety, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms; and each R 2 is selected, independently from one another, from the group consisting of straight or branched C 1 - 4 alkoxy moiety, halogen, and straight or branched C 1 - 4 alkyl moiety, and n is an integer from zero to 2, with the proviso that if
- R2 3 is selected from the group consisting of hydrogen, straight or branched Ci- 8 alkyl moiety, benzyl, (phenyl) ethyl and phenyl, the benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties selected, independently from one another, from the group consisting of straight or branched C 1 - 4 alkyl moiety, straight or branched C 1 - 4 alkoxy moiety, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms; and each R 3 is selected, independently from one another, from the group consisting of straight or branched C 1 - 4 alkoxy moiety, halogen, and straight or branched C1-4 alkyl moiety, and n is an integer from zero to 2, with the proviso that if n is
- Ri 4 is -CHR 34 R 44 wherein R 44 is hydrogen or a carbon-carbon bond, with the proviso that when R 44 is hydrogen R 34 is Ci_ 4 alkoxy moiety, C 1 - 4 hydroxyalkoxy moiety, C2-10 1-alkynyl moiety, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when R 44 is a carbon-carbon bond R 44 and R 34 together form a tetrahydrofuranyl group optionally substituted with one or more substituents selected, independently from one another, from the group consisting of hydroxy and Ci_ 4 hydroxyalkyl moities;
- R 24 is selected from the group consisting of hydrogen, Ci_ 4 alkyl, phenyl, wherein the phenyl is optionally substituted by one or two moieties selected, independently from one another, from the group consisting of straight or branched C 1 - 4 alkyl moiety, straight or branched Ci_ 4 alkoxy moiety, and halogen; and R 4 is selected from the group consisting of hydrogen, straight or branched C 1 -4 alkoxy moiety, halogen, and straight or branched C 1 - 4 alkyl moiety;
- Ris is selected from the group consisting of hydrogen; straight or branched Ci- 10 alkyl moiety and substituted straight or branched Ci-10 alkyl moiety, wherein the substituent is selected from the group consisting of C 3 - 6 cycloalkyl and C 3 _ 6 cycloalkyl substituted by straight or branched C 1 - 4 alkyl moiety; straight or branched C 2 - 10 alkenyl and substituted straight or branched C 2 - 10 alkenyl moiety, wherein the substituent is selected from the group consisting of C3- 6 cycloalkyl and C 3 - 6 cycloalkyl substituted by straight or branched Ci.
- Ci- ⁇ hydroxyalkyl alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties selected, independently from one another, from the group consisting of Ci_ 4 alkyl moiety, Ci_ 4 alkoxy moiety, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
- R 35 is selected from the group consisting of C 1 - 4 alkoxy moiety, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms; C 1 - 4 haloalkyl moiety; alkylamido wherein the alkyl group contains one to about four carbon atoms; amino; amino substituted with C3.- 4 alkyl or C 1 - 4 hydroxyalkyl; azido; C1- 4 alkylthio;
- R 55 and R 45 are selected, independently from one another, from the group consisting of hydrogen, Ci_ 4 alkyl moiety, phenyl, wherein said phenyl is optionally substituted by one or two moieties selected, independently from one another, from the group consisting of straight or branched C 1 - 4 alkyl moiety, straight or branched Ci_ 4 alkoxy moiety, and halogen; and
- R 5 is selected from the group consisting of hydrogen, straight or branched C ⁇ _ 4 alkoxy moiety, halogen, and straight or branched C 1 - 4 alkyl containing moiety.
- the Ci_ 4 alkyl moiety is for example methyl, ethyl, propyl, 2-methylpropyl and butyl.
- the Ci_ 4 alkyl moiety is selected in the group consisting in methyl, ethyl and 2methyl- propyl .
- the alkoxy moiety is selected in the group consisting in methoxy, ethoxy and ethoxymethyl .
- n is zero or one.
- R 1 -R 5 groups are hydrogen.
- R 11 -R 15 groups are selected in the group consisting in 2-methylpropyl and 2- hydroxy-2-methylpropyl .
- R 2 i ⁇ R 25 groups are selected in the group consisting in hydrogen, Ci- 6 alkyl moiety, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms.
- Most preferred R 2 1-R 25 groups are selected in the group consisting in hydrogen, methyl, or ethoxymethyl.
- the IH- imidazo [4 , 5-c] quinolin-4-amine-derivative of the present invention is a compound defined the following general formula VI :
- Rt is selected from the group consisting of hydrogen, straight or branched Ci_ 4 alkoxy moiety, halogen, and straight or branched Ci_ 4 alkyl;
- Ru is 2-methylpropyl or 2-hydroxy-2-methylpropyl
- Rv is hydrogen, Ci_ 6 alkyl, or alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms.
- Rt is hydrogen
- Ru is 2-methylpropyl or 2hydroxy-2-methylpropyl
- Rv is hydrogen, methyl or ethoxymethyl .
- the IH- imidazo [4 , 5-c] quinolin-4-amine-derivative of the present invention is a compound selected in the following group :
- reference to a IH- imidazo [4, 5-c] quinolin-4-amine-derivative can include the compound in any pharmaceutically acceptable form, including any isomer (e. g., diastereomer or enantiomer) , salt, solvate, polymorph, and the like.
- reference to the compound can include each of the compound's enantiomers as well as racemic mixtures of the enantiomers.
- the recombinant viral vaccine and more particularly the recombinant viral vector does not comprise an immunostimulatory motif or backbone that induces by itself an immune response especially a nucleotide sequence that possess immunostimulatory motif or backbone such as CpG, polyG, polyT, TG, methylated CpG, CpI and T rich motif or phosphorothioate backbones (see US 2003/0139364, US 6,207,646 or WO 01/22972 the content of which is incorporated herein by reference.
- an immunostimulatory motif or backbone such as CpG, polyG, polyT, TG, methylated CpG, CpI and T rich motif or phosphorothioate backbones
- the lH-imidazo [4,5- c] quinolin-4-amine derivative concentration in the final recombinant viral vaccine will be from about 0.0001% to about 10% (unless otherwise indicated, all percentages provided herein are weight/weight with respect to the total formulation), from about 0.01% to about 2%, more particularly from about 0.06 to about 1%, preferably from about 0.1 to about 0.6%.
- the appropriate dosage of recombinant viral vector can be adapted as a function of various parameters, in particular the mode of administration; the composition employed; the age, health, and weight of the host organism; the nature and extent of symptoms; kind of concurrent treatment; the frequency of treatment; and/or the need for prevention or therapy. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by a practitioner, in the light of the relevant circumstances.
- suitable dosage for a MVA-containing composition varies from about 10 4 to 10 10 pfu (plaque forming units) , desirably from about 10 5 and 10 8 pfu whereas adenovirus-comprising composition varies from about 10 5 to 10 13 iu (infectious units), desirably from about 10 7 and 10 12 iu.
- a composition based on vector plasmids may be administered in doses of between 10 ⁇ g and 20 mg, advantageously between 100 ⁇ g and 2 mg.
- the composition is administered at dose(s) comprising from 5xlO 5 pfu to 5xlO 7 pfu of MVA vaccinia vector.
- the dosing regimen may depend at least in part on many factors known in the art including but not limited to the nature of the imidazo [4,5-c] quinolin-4-amine derivative and recombinant viral vector used, the nature of the carrier, the amount of the imidazo [4,5-c] quinolin-4-amine derivative and recombinant viral vector being administered, the state of the subject's immune system (e.g., suppressed, compromised, stimulated), and the method of administering the imidazo [4,5- c] quinolin-4-amine derivative and/or of recombinant viral vector compounds. Accordingly it is not practical to set forth generally the dosing regimen effective for increasing the efficacy of a recombinant viral vaccine for all possible applications.
- the imidazo [4,5-c] quinolin-4-amine derivative and/or recombinant viral vector compounds may be administered, for example, once to about once daily, although in some embodiments the imidazo [4,5-c] quinolin-4-amine derivative and/or recombinant viral vector compounds may be administered at a frequency outside this range. In certain embodiments, the imidazo [4,5-c] quinolin-4-amine derivative and/or recombinant viral vector compounds may be administered from about once per week to about once per day.
- the imidazo [4,5-c] quinolin-4-amine derivative and/or recombinant viral vector compounds are administered once every weeks.
- the imidazo [4,5-c] quinolin-4-amine derivative and recombinant viral vector is administered 1 to 10 times at weekly intervals.
- the imidazo [4,5-c] quinolin-4- amine derivative and recombinant viral vector, or any composition containing it is administered 3 times at weekly intervals by subcutaneous route.
- the invention provides a method of increasing an immune response to an antigen in a patient, said method comprising administration, either sequentially or simultaneously, of (i) a recombinant viral vector expressing in vivo at least one heterologous nucleotide sequence, especially an heterologous nucleotide sequence encoding an antigen and (ii) an imidazo [4,5-c] quinolin-4-amine derivative .
- the invention provides a method of preventing occurrence of and/or of treating cancer in a patient, said method comprising administration, either sequentially or simultaneously, of (i) a recombinant viral vector expressing in vivo at least one heterologous nucleotide sequence, especially an heterologous nucleotide sequence encoding an antigen and (ii) an imidazo [4,5-c] quinolin-4- amine derivative.
- the invention provides a method of preventing occurrence of and/or of treating infectious disease in a patient, said method comprising administration, either sequentially or simultaneously, of (i) a recombinant viral vector expressing in vivo at least one heterologous nucleotide sequence, especially an heterologous nucleotide sequence encoding an antigen and (ii) an imidazo [4,5-c] quinolin-4- amine derivative.
- said infectious disease is a viral induced disease, such as for example disease induced by HIV, HCV, HBV, HPV, and the like.
- an imidazo [4,5-c] quinolin4-amine derivative in the manufacture of a recombinant viral vaccine for the enhancement of an immune response to an antigen encoded by a recombinant viral vector, said recombinant viral vector being administered either sequentially or simultaneously with said derivative.
- administered sequentially means that the recombinant viral vector [compound (i) ] and the imidazo [4,5-c] quinolin4- amine derivative [compound (ii) ] of the present recombinant viral vaccine are administered independently from one another ; e.g. a first administration of one of the said compound and a separate second administration consisting in administration of the second compound.
- the first administration can be done prior to, concurrently with or subsequent to the second administration, and vice- versa.
- the therapeutic composition administration and second administration can be performed by different or identical delivery routes (systemic delivery and targeted delivery, or targeted deliveries for example) . In a preferred embodiment, each should be done into the same target tissue and most preferably by parenteral route.
- the administration of the recombinant viral vector and of the imidazo [4,5-c] quinolin- 4-amine derivative is substantially simultaneous. And more preferably, both compounds are co-administered.
- the imidazo [4,5-c] quinolin-4- amine derivative is administered before the administration of the recombinant viral vector.
- "before” means from about 5 min to about 2 weeks, more particularly from about 1 hour to about 1 week, more particularly from about 6 hours to about 48 hours.
- the recombinant viral vaccine of the invention is administered in patient as a pharmaceutically acceptable solution, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants (e.g. alum, BCG, immune response modifiers) , and optionally other therapeutic ingredients .
- a pharmaceutically acceptable solution may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants (e.g. alum, BCG, immune response modifiers) , and optionally other therapeutic ingredients .
- pharmaceutically-acceptable carrier means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal.
- carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
- the components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.
- the recombinant viral vaccine can be administered by any ordinary route for administering medications.
- a variety of administration routes are available. The particular mode selected will depend, of course, upon the particular recombinant viral vaccine content, the particular condition being treated and the dosage required for therapeutic efficacy.
- the methods of this invention may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an immune response without causing clinically unacceptable adverse effects. Preferred modes of administration are discussed herein.
- an effective amount of the IH-imidazo [4, 5-c] quinolin-4-amine derivative can be administered to a subject by any mode that delivers the agent to the desired surface, e.g., mucosal, systemic and under any form, e.g. cream, solution.
- the recombinant viral vaccine, or its separate compounds (i) and (ii) may be used according to the invention by a variety of modes of administration, including systemic, topical and localized administration.
- Injection can be performed by any means, for example by subcutaneous, intradermal, intramuscular, intravenous, intraperitoneal, intratumoral, intravascular, intraarterial injection or by direct injection into an artery (e.g. by hepatic artery infusion) or a vein feeding liver (e.g. injection into the portal vein) .
- Injections can be made with conventional syringes and needles, or any other appropriate devices available in the art.
- the active compound, or any composition containing it may be administered via a mucosal route, such as the oral/alimentary, nasal, intratracheal, intrapulmonary, intravaginal or intra-rectal route.
- Topical administration can also be performed using transdermal means (e.g. patch, cream and the like).
- transdermal means e.g. patch, cream and the like.
- intramuscular and subcutaneous administrations constitute the preferred routes.
- the recombinant viral vaccine can be formulated readily by combining the active compound (s) with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
- Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP) .
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers .
- Recombinant viral vaccine which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.
- the recombinant viral vaccine when it is desirable to deliver it systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi- dose containers, with an added preservative.
- the recombinant viral vaccine may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Recombinant viral vaccine for parenteral administration includes aqueous solutions of the active compounds in water-soluble form.
- suspensions of the active compounds (i) and/or (ii) may be prepared as appropriate oily injection suspensions.
- Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the active compounds (i) and/or (ii) may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- a suitable vehicle e.g., sterile pyrogen-free water
- the recombinant viral vaccine may also be formulated ' in rectal or vaginal compositions such as suppositories or retention enemas, e.g.-, containing conventional suppository bases such as cocoa butter or other glycerides.
- the recombinant viral vaccine may also be formulated as a depot preparation.
- Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- suitable polymeric or hydrophobic materials for example as an emulsion in an acceptable oil
- ion exchange resins for example, as an emulsion in an acceptable oil
- sparingly soluble derivatives for example, as a sparingly soluble salt.
- the recombinant viral vaccine also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- Suitable liquid or solid recombinant viral vaccine forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin.
- compositions also include granules, powders, tablets, coated tablets, (micro) capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above.
- auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above.
- the lH-imidazo [4 , 5-c] quinolin-4-amine derivative may be administered per se or in the form of a pharmaceutically acceptable salt.
- the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof.
- Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic.
- salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.
- Suitable buffering agents include: acetic acid and a salt (1-2% w/v) ; citric acid and a salt (1-3% w/v) ; boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v).
- Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).
- the recombinant viral vaccine may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the compounds (i) and (ii) into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, purpose of the immunization (i.e.
- prophylactic or therapeutic , nature and severity of the disorder, age and body weight of the patient, different doses may be necessary.
- the administration of a given dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units. Multiple administrations of doses at specific intervals of weeks or months apart are usual for boosting the antigen-specific responses.
- Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compounds of the recombinant viral vaccine, increasing convenience to the subject and the physician.
- Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly (lactide-glycolide) , copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides .
- Microcapsules of the foregoing polymers containing drugs are described in, for example, US 5,075,109.
- Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di-, and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like.
- lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di-, and tri-glycerides
- hydrogel release systems sylastic systems
- peptide based systems peptide based systems
- wax coatings such as compressed tablets using conventional binders and excipients; partially fused implants; and the like.
- erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in US 4,452,775, 4,675,189, and 5,736,152
- diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in US 3,854,480, 5,133,974 and 5,407,686.
- pump-based hardware delivery systems can be used, some of which are adapted for implantation .
- the administration form of the recombinant viral vector [compound (i) ] and of the lH-imidazo [4 , 5-c] quinolin-4-amine derivative [compound (ii) ] can be identical or different for one said recombinant viral vaccine according to the invention (e.g. compound (i) administered as a solution and compound (ii) administered as a cream).
- kits in other aspects, relate to kits.
- One kit of the invention includes a container containing (i) at least one recombinant viral vector of the invention and a container containing (ii) at least one lH-imidazo [4 , 5-c] quinolin-4- amine derivative and instructions for timing of administration of the compounds.
- the container may be a single container housing both (i) at least one recombinant viral vaccine and (ii) at least one lH-imidazo [4, 5-c] quinolin-4-amine derivative together or it may be multiple containers or chambers housing individual dosages of the compounds (i) and (ii) , such as a blister pack.
- the kit also has instructions for timing of administration of the recombinant viral vaccine.
- the instructions would direct the subject to take the recombinant viral vaccine at the appropriate time.
- the appropriate time for delivery of the recombinant viral vaccine may be as the symptoms occur.
- the appropriate time for administration of the recombinant viral vaccine may be on a routine schedule such as monthly or yearly.
- the compounds (i) and (ii) may be administered simultaneously or separately as long as they are administered close enough in time to produce a synergistic immune response.
- the method or use of the invention can be carried out in conjunction with one or more conventional therapeutic modalities (e.g. radiation, chemotherapy and/or surgery) .
- the use of multiple therapeutic approaches provides the patient with a broader based intervention.
- the method of the invention can be preceded or followed by a surgical intervention.
- it can be preceded or followed by radiotherapy (e.g. gamma radiation) .
- radiotherapy e.g. gamma radiation
- Those skilled in the art can readily formulate appropriate radiation therapy protocols and parameters which can be used (see for example Perez and Brady, 1992, Principles and Practice of Radiation Oncology, 2nd Ed. JB Lippincott Co; using appropriate adaptations and modifications as will be readily apparent to those skilled in the field) .
- the method or use of the invention is associated to chemotherapy with one or more drugs (e.g. drugs which are conventionally used for treating or preventing HPV infections, HPV-associated pathologic conditions) .
- the present Invention further concerns a method for improving the treatment of a cancer patient which is undergoing chemotherapeutic treatment with a chemotherapeutic agent, which comprises co-treatment of said patient along with a recombinant viral vaccine as above disclosed.
- the method or use of the invention is carried out according to a prime boost therapeutic modality which comprises sequential administration of one or more primer composition (s) and one or more booster composition (s) .
- the priming and the boosting compositions use different vehicles which comprise or encode at least an antigenic domain in common.
- the priming composition is initially administered to the host organism and the boosting composition is subsequently administered to the same host organism after a period varying from one day to twelve months.
- the method of the invention may comprise one to ten sequential administrations of the priming composition followed by one to ten sequential administrations of the boosting composition. Desirably, injection intervals are a matter of one week to six months.
- compositions based on HPV early polypeptide can be administered by a mucosal route whereas recombinant viral vaccine is preferably injected, e.g. subcutaneous injection for a MVA vector.
- the ability to induce or stimulate an anti-HPV immune response upon administration in an animal or human organism can be evaluated either in vitro or in vivo using a variety of assays which are standard in the art.
- assays which are standard in the art.
- Measurement of cellular immunity can be performed by measurement of cytokine profiles secreted by activated effector cells including those derived from CD4+ and CD8+ T-cells (e.g.
- IL-IO or IFN gamma-producing cells by ELIspot), by determination of the activation status of immune effector cells (e.g. T cell proliferation assays by a classical [ 3 H] thymidine uptake) , by assaying for antigen- specific T lymphocytes in a sensitized subject (e.g. peptide- specific lysis in a cytotoxicity assay) .
- the ability to stimulate a humoral response may be determined by antibody binding and/or competition in binding (see for example Harlow, 1989, Antibodies, Cold Spring Harbor Press) .
- the method of the invention can also be further validated in animal models challenged with an appropriate tumor-inducing agent (e.g. HPV- E6 and E7-expressing TCl cells) to determine anti-tumor activity, reflecting an induction or an enhancement of an anti-HPV immune response.
- an appropriate tumor-inducing agent e.g. HPV- E6 and E7-expressing TCl cells
- Disease conditions which may especially be treated in accordance with the present invention are for example cervical cancer or precursor lesions of this malignant neoplasia, which are called cervical intraepithelial neoplasia (CIN) or squamous intraepithelial lesions (SIL).
- CIN cervical intraepithelial neoplasia
- SIL squamous intraepithelial lesions
- the recombinant viral vaccine of the invention may also be useful in the treatment of asymptomatic infections of the cervix in patients identified by DNA diagnosis, or asymptomatic infections that are assumed to remain after surgical treatment of cervical cancer, CIN or SIL, or asymptomatic infections presumed to exist following epidemiological reasoning.
- the disease conditions to be treated also include genital warts, and common warts and plantar warts.
- All of these conditions are also caused by a large number of other HPV types, and the agents, compounds and methods of the invention may also be usefully directed against these viruses. All of these lesions presumably derive from asymptomatic infections, that are most often not diagnosed. The present invention may also be usefully targeted against all of these asymptomatic infections.
- Figures la/b/c/d Therapeutic effect of a combination between topical administration of Imiquimod with subcutaneous injection of MVATG8042.
- Figure Ib Experiment 1 : 2.10 5 TCI sc, 3sc injections with 5.10 6 pfu, 15 mice per group ;
- Figure Ic Experiment 2 : 2.10 5 TCI sc, 3sc injections with 5.10 6 or 5.10 5 pfu, 15 mice per group;
- Figure Id Experiment 3 : 2.10 5 TCI sc, 3sc injections with 5.10 6 , 15 mice per group
- Figures 2a/2b Measure of the frequence of E7/E6 specific IFN ⁇ secreting lymphocytes.
- Figure 2b E6/E7 specific INFgamma/Elispot ThI response.
- Figure 3 IL-4 ELISPOT assay. E7 specific IL-4/Elispot Th2 response .
- Figure 4a/4b Flow cytometry analysis of R9F-specific CD8+ T cells. Measure of the frequence of Tet_R9F + E7 specific CD8 + T cells.
- FIG. 5a/5b E7-specific humoral immune response. Measure of Thl/Th2 isotype IgG switch.
- FIG. 6 MVA-specific neutralizing antibody titer (NAT50) .
- Figure 7 Therapeutic effect of Aldara + MVATG9931 combination in a RenCa-Mucl tumour model.
- Figure 8 Effect of imiquimod on MUCl-specific ThI type T cell responses against short or long epitopes.
- Figure 9 IL-4 elispot assay : Effect of imiquimod on MUC-I specific Th2 type T cell responses.
- FIG. 10 MUCl specific humoral immune response (Isotype Switch) : Effect of imiquimod on MUC 1 specific humoral response.
- Viruses were maintained at -80 0 C until the day of injection. The viral suspension was rapidly thawed immediately prior to dilution and administration.
- Viruses were diluted in buffer Tris/HCl 10 mM, saccharose 5% (w/v) , 10 mM NaGIu, 50 mM NaCl, pH8,0 in order to obtain the required dose in a lOO ⁇ l volume.
- the animals were 6-weeks-old upon arrival. At the beginning of experimentation, they were 7-week-old.
- the animals were housed in a single, exclusive room, air-conditioned to provide a minimum of 11 air changes per hour.
- the temperature and relative humidity ranges were within 2O 0 C and 24°C and 40 to 70 % respectively. Lighting was controlled automatically to give a cycle of 12 hours of light and 12 hours of darkness. Specific pathogen free status was checked by regular control of sentinel animals. Throughout the study the animals had access ad libitum to sterilized diet type RMl (Dietex France, Saint Gratien) . Sterile water was provided ad libitum via bottles.
- TCl tumour cells obtained from C57B16 mice lung, have been transduced with two retroviruses : LXSN16E6E7 expressing E6 and E7 from HPVl 6 and pVEJB expressing the ras gene.
- the cells were cultured in DMEM containing 0.5 mg/ml G418 and 0.2 mg/ml Hygromycine.
- Adherents cells were removed by trypsine treatment and after 3 washings, tumour challenge were performed subcutaneously with 2.10 5 TCl viable cells.
- AldaraTM is the brand name for imiquimod. Each gram of the 5% cream contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerine, xanthan gum, purified water, benzyl alcohol, methylparaben and propylparaben.
- mice 15 C57B16 female mice were challenged subcutaneously in the right flank with 2.10 5 TCl cells at Dl. Mice were treated three times, subcutaneously at three distant sites, with 5.10 6 pfu or 5.10 5 pfu of vaccinia virus at D8, D15 and D22.
- Imiquimod (Aldara 5% cream; 3M Pharmaceuticals) was applied topically just before each immunization over the sites of injection to the shaved skin of mice (approx. 1 cm 2 ) . Each mouse received approximately 0,8 mg or 1,6 mg/mouse of active imiquimod per immunization. Tumour growth was monitored, twice a week during 80 days, with a calliper. Mice were euthanized for ethical reasons when their tumour size was superior to 25 mm of diameter or when they showed pain even if the tumour was smaller.
- mice 3 tumor-free C57B16 female mice were vaccinated subcutaneously at three distant sites with 5.10 7 pfu or 5.10 6 pfu of vaccinia virus at Dl, D8 and D15. This dose was used to optimize the detection of cellular immunity against HPV specific antigens.
- Imiquimod was applied topically just before each immunization over the sites of injection to the shaved skin of mice (approx. 1 cm 2 ) . Each mouse received approximately 0,8 mg or 1,6 mg /mouse of active imiquimod per immunization. Spleen and serum were removed at D22 for immunological analysis.
- Fresh spleen cells were prepared using a Cell Strainer (BD Falcon) . All the peptides were synthesized by Neosystem at the immunograde level (10 mg) . Each peptide was dissolved in DMSO at 10 mg/ml and store at 4 0 C. Elispot was carried out using the Mabtech AB mouse IFNgamma ELISPOT PLUS kit or mouse IL- 4 ELISPOT PLUS kit (Mabtech, ' France) according to the manufacturer's instructions. A 96-well nitrocellulose plate was coated with 3 ⁇ g/ml monoclonal rat anti-mouse IFNgamma antibody (Clone R4-6A2; Pharmingen, cat.
- nr551216, Lot M072862; lOO ⁇ l/well) in Sodium Carbonate Buffer The plates were incubated overnight at 4 0 C or Ih at 37 0 C. Plates were washed three times with DMEM 10% FCS and saturated 2 hours at 37 0 C with lOO ⁇ l DMEM 10% FCS/ well. Splenocytes were plated at a concentration of 10 6 cells/lOO ⁇ l. Interleukine 2 was added to all the wells at a concentration of 6U/50 ⁇ l/well (R&D Systems) lOng/ml) . ConcanavalinA was used as positive control (5 ⁇ g/ml) .
- HPV specific peptides were used at a concentration of 5 ⁇ g/ml.
- the plates were incubated 48 hours at 37 0 C, 5% C02.
- the plate was washed one time with PBS IX and 5 times with PBS-Tween 0.05%.
- Biotinylated Anti-mouse IFNgamma (clone XMGl.2, Pharmingen) was added at the concentration of 0.3 ⁇ g/100 ⁇ l/well and incubated 2 hours at room temperature under slow agitation.
- the plate was washed 5 times with PBS- Tween 0.05%.
- Extravidin AKP Sigma, St.
- D38L (E7; Db) is a 38 amino acid-long E7-specific peptide. Recombinant purified E7 protein has also been used in the different ELISPOT assays.
- E7 purified protein (P#2101 cahier PCOOOOl; page 157; Oct.2002) .
- the protein was diluted in coating buffer (20OmM NaHCO 3 , 8OmM Na 2 CO 3 , pH 9.5) and lOO ⁇ l were added per well.
- TMB solution (10 ml) 140 ⁇ l TMB + 2 ⁇ l H 2 O 2 + 5ml Na Acetate (0,1M) + 5ml Citrate (0,1M) *The reaction was stopped by adding lOO ⁇ l of 0.8M H 2 SO 4 /well. Absorbance was measured at 450nm (Genesys system).
- BHK-21 hamster fibroblast, Ref ATCC : CCL-IO
- MVA-GFP (MVATGl5938) : Reporter green fluorescent protein was inserted in MVA deletion III under the control of pllK7.5 promoter.
- Step 1 Neutralizing serum:
- Step 2 Seroneutralization assay (SOP Measurement of neutralizing anti-MVA antibodies titer)
- -Plasma were serially diluted in culture medium (range of dilution 5Ox to 320Ox) and incubated in a 96-well microplate with MVA-GFP (5xlO 3 pfu/well) for Ih at 37°C (neutralization step) .
- MVA-GFP 5xlO 3 pfu/well
- BHK-21 cells (10 5 cells/well) were then seeded and incubated for an additional 16-18 hours at 37°C, 5%CO 2 .
- the neutralizing antibody titre is the titre at which 50% viral activity is inhibited.
- Neutralizing Antibody Titres (NAT 50 ) were calculated using the Spearman-Karber method.
- Viruses were received from the Molecular Immunology Department and then were maintained at -80 0 C until the day of injection. The viral suspension was rapidly thawed immediately prior to dilution and administration.
- Viruses were diluted in TG0008 buffer (Tris/HCl 10 mM, saccharose 5% (w/v) , 10 mM NaGIu, 50 mM NaCl, pH8,0) in order to obtain the required dose in a lOO ⁇ l volume.
- the animals were ⁇ -weeks-old upon arrival. At the beginning of experimentation, they were 7-week-old. The animals were housed in a single, exclusive room, air- conditioned to provide a minimum of 11 air changes per hour. The temperature and relative humidity ranges were within 20°C and 24 0 C and 40 to 70 % respectively. Lighting was controlled automatically to give a cycle of 12 hours of light and 12 hours of darkness. Throughout the study the animals had access ad libitum to sterilized diet type RMl (Dietex France, Saint Gratien) . Sterile water was provided ad libitum via bottles.
- RMl Dietex France, Saint Gratien
- RenCa-MUCl tumor cells RenCa is an experimental murine kidney cancer model . RenCa cells were transfected with pHMG-ETAtm (MUC-I) and pY3 (hygromycin B resistance) using the classical Ca 2+ phosphate transfection method. Clones were selected after clonal dilution in DMEM (Dulbecco Modified) supplemented with 10% inactivated foetal calf serum, L-glutamin (2 mM) , gentamycin (0,04 g/1) and hygromycin (600 ⁇ g/ml, Roche Diagnostic) .
- DMEM Disulbecco Modified
- MUC-I expression was made by cytofluorimetry analysis (using a FACScan, Becton Dickinson) with H23 monoclonal antibody.
- Adherents cells were removed by PBS/EDTA treatment and after 3 washings, tumor challenge were performed subcutaneously with 3.10 5 RenCa-MUCl (clone 4) viable cells .
- mice 15 B6D2 female mice were challenged subcutaneously in the right flank with 3.10 s RenCa-MUCl cells at Dl. Mice were treated three times, subcutaneously at three distant sites, with 5.10 7 pfu of poxvirus (MVA strain) at D4, 11 and 18. Imiguimod was applied topically just before each immunization over the sites of injection to the shaved skin of mice (approx. 10 cm 2 ) . Each mouse received approximately 1 mg/mouse of active imiquimod per immunization. Tumour growth was monitored, twice a week during 80 days, with a calliper. Mice were euthanized for ethical reasons when their tumour size was superior to 25 mm of diameter or when they showed pain even if the tumour was smaller.
- mice were vaccinated subcutaneously at three distant sites with 5.10 7 pfu of poxvirus (MVA strain) at Dl, 8 and 15. This dose was used to optimize the detection of cellular immunity against MUCl specific antigens.
- Imiquimod was applied topically just before each immunization over the sites of injection to the shaved skin of mice (approx. 10 cm 2 ). Each mouse received approximately 1 mg/mouse of active imiquimod per immunization. Spleen and serum were removed at D22 for immunological analysis .
- Fresh spleen cells were prepared using Lympholite purification buffer. All the peptides were synthesized by Neosystem at the immunograde level (10 mg) . Each peptide was dissolved in DMSO at 10 mg/ml and store at 4 0 C. A 96-well nitrocellulose plate was coated with 3 ⁇ g/ml monoclonal rat anti-mouse IFNgamma antibody (Clone R4-6A2; Pharmingen, cat. nr551216, Lot M072862; lOO ⁇ l/well) in Sodium Carbonate Buffer. The plates were incubated overnight at 4 0 C or Ih at 37 0 C.
- Biotinylated Anti-mouse IFNgamma (clone XMGl.2, Pharmingen) was added at the concentration of 0.3 ⁇ g/100 ⁇ l/well and incubated 2 hours at room temperature under slow agitation. The plate was washed 5 times with PBS- Tween 0.05%. Extravidin AKP (Sigma, St. Louis, MO) diluted at 1/5000 in PBS-Tween0.05%-FCSl% was also added to the wells (lOO ⁇ l/well) . The plate was incubated 45 minutes at room temperature and then washed 5 times with PBS-Tween 0.05%. IFNgamma secretion was revealed with Biorad Kit. lOO ⁇ l substrate (NBT+BCIP) was added per well and plate was left at room temperature for H hour. The plate was washed with water and put to dry overnight at room temperature. Spots were counted using a dissecting microscope.
- Fresh spleen cells were prepared using Lympholite purification buffer. All the peptides were synthesized by Neosystem at the immunograde level (10 mg) . Each peptide was dissolved in DMSO at 10 mg/ml and store at 4°C. A 96-well nitrocellulose plate was coated with 3 ⁇ g/ml monoclonal anti- mouse IL-4 antibody (Pharmingen, cat. nr551878, Lot 27401 ; lOO ⁇ l/well) in Sodium Carbonate Buffer . The plates were incubated overnight at 4 0 C or Ih at 37 0 C. Plates were washed three times with DMEM 10% FCS and saturated 2 hours at 37 0 C with lOO ⁇ l DMEM 10% FCS/ well.
- Splenocytes were plated at a concentration of 10 6 cells/lOO ⁇ l.
- Interleukine 2 was added to all the wells at a concentration of 6U/50 ⁇ l/well (R&D Systems 10 ng/ml) .
- ConcanavalinA was used as positive control (5 ⁇ g/ml) .
- MUCl specific peptides were used at a concentration of 5 ⁇ g/ml.
- the plates were incubated 48 hours at 37 0 C, 5% CO2. The plate was washed one time with PBS IX and 5 times with PBS-Tween 0.05%.
- Biotinylated Anti-mouse IL-4 (Pharmingen) was added at the concentration of 0.2 ⁇ g/100 ⁇ l/well and incubated 2 hours at room temperature under slow agitation. The plate was washed 5 times with PBS-Tween 0.05%. Extravidin AKP (Sigma, St. Louis, MO) diluted at 1/5000 in PBS-TweenO .05%-FCSl% was also added to the wells (lOO ⁇ l/well) . The plate was incubated 45 minutes at room temperature and then washed 5 times with PBS-Tween 0.05%. IFNgamma secretion was revealed with Biorad Kit. lOO ⁇ l substrate (NBT+BCIP) was added per well and plate was left at room temperature for H hour. The plate was washed with water and put to dry overnight at room temperature. Spots were counted using a dissecting microscope.
- TMB solution (10 ml) 140 ⁇ l TMB + 2 ⁇ l H 2 O 2 + 5ml Na Acetate (0,1M) + 5ml Citrate (0,1M)
- Figure 7 illustrates the therapeutic effect of Aldara + MVATG9931 combination in a renCa-Mucl tumour model.
- An iramunogenicity study was also performed in parallel to look for the induction of both cellular and humoral responses against MUCl antigen. Mice were vaccinated as described in the protocol section.
- MUCl-specific IL-4 secreting cells was enumerated using an ELISPOT assay.
- MUCl restricted peptides were used to monitored both CD4 and CD8 T cell response after immunization.
- pre-treatment with a topical administration of Aldara reduce significantly the number of Th2-based T cell response obtained with MVATG9931 alone ( Figure 9) .
- the measure of the humoral response against the MUCl antigen was also performed by ELISA.
- the IgG isotype switch was analysed. MUCl-specific IgGl and IgG2a were detected ( Figure 10) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0713711-7A BRPI0713711A2 (en) | 2006-06-20 | 2007-06-15 | recombinant viral vaccine, vaccination kit, and method for using at least one compound |
KR1020087030973A KR101141333B1 (en) | 2006-06-20 | 2007-06-15 | Recombinant Viral Vaccine |
MX2008016036A MX2008016036A (en) | 2006-06-20 | 2007-06-15 | Recombinant viral vaccine. |
AU2007263281A AU2007263281B2 (en) | 2006-06-20 | 2007-06-15 | Recombinant viral vaccine |
CA2656266A CA2656266C (en) | 2006-06-20 | 2007-06-15 | Recombinant viral vaccine |
JP2009515748A JP2009541236A (en) | 2006-06-20 | 2007-06-15 | Recombinant virus vaccine |
US12/306,227 US20100129403A1 (en) | 2006-06-20 | 2007-06-15 | Recombinant viral vaccine |
EP07764675A EP2029169A2 (en) | 2006-06-20 | 2007-06-15 | Recombinant viral vaccine |
IL195683A IL195683A0 (en) | 2006-06-20 | 2008-12-03 | Recombinant viral vaccine |
NO20090194A NO20090194L (en) | 2006-06-20 | 2009-01-13 | Recombinant viral vaccine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06360028 | 2006-06-20 | ||
EP06360028.2 | 2006-06-20 | ||
US85296406P | 2006-10-20 | 2006-10-20 | |
US60/852,964 | 2006-10-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007147529A2 true WO2007147529A2 (en) | 2007-12-27 |
WO2007147529A3 WO2007147529A3 (en) | 2008-02-28 |
Family
ID=38657260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/005303 WO2007147529A2 (en) | 2006-06-20 | 2007-06-15 | Recombinant viral vaccine |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100129403A1 (en) |
EP (1) | EP2029169A2 (en) |
JP (1) | JP2009541236A (en) |
KR (1) | KR101141333B1 (en) |
CN (1) | CN101472610A (en) |
AU (1) | AU2007263281B2 (en) |
BR (1) | BRPI0713711A2 (en) |
CA (1) | CA2656266C (en) |
CR (1) | CR10571A (en) |
IL (1) | IL195683A0 (en) |
MA (1) | MA30581B1 (en) |
MX (1) | MX2008016036A (en) |
NO (1) | NO20090194L (en) |
RU (1) | RU2453335C2 (en) |
WO (1) | WO2007147529A2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011015656A2 (en) | 2009-08-07 | 2011-02-10 | Transgene Sa | Composition for treating hbv infection |
WO2013007772A1 (en) | 2011-07-12 | 2013-01-17 | Transgene Sa | Hbv polymerase mutants |
WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
WO2014009438A2 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
WO2015104380A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
WO2018122088A1 (en) | 2016-12-28 | 2018-07-05 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | Oncolytic viruses expressing agents targeting metabolic immune modulators |
EP3552615A1 (en) | 2014-07-16 | 2019-10-16 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
WO2021040056A1 (en) | 2019-08-29 | 2021-03-04 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012145577A1 (en) * | 2011-04-20 | 2012-10-26 | Merial Limited | Adjuvanted rabies vaccine with improved viscosity profile |
CN103409451A (en) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | Method for loading tumor antigen peptide to dendritic cell (DC) in targeting manner |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4689338A (en) | 1983-11-18 | 1987-08-25 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
EP0385630A2 (en) | 1989-02-27 | 1990-09-05 | Riker Laboratories, Inc. | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
WO1992015672A1 (en) | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
WO1994017043A1 (en) | 1993-01-29 | 1994-08-04 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
WO1995027780A1 (en) | 1994-04-06 | 1995-10-19 | Virogenetics Corporation | Poxvirus-canine distemper virus (cdv) recombinants and compositions and methods employing the recombinants |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
WO2002024225A1 (en) | 2000-09-20 | 2002-03-28 | Glaxo Group Limited | Use of immidazoquinolinamines as adjuvants in dna vaccination |
US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
WO2003080114A2 (en) | 2002-03-19 | 2003-10-02 | Powdermed Limited | Imidazoquinoline adjuvants for vaccines |
WO2005018574A2 (en) | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
US6913752B2 (en) | 2000-11-23 | 2005-07-05 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant |
WO2006042254A2 (en) | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
-
2007
- 2007-06-15 CA CA2656266A patent/CA2656266C/en not_active Expired - Fee Related
- 2007-06-15 AU AU2007263281A patent/AU2007263281B2/en not_active Ceased
- 2007-06-15 BR BRPI0713711-7A patent/BRPI0713711A2/en not_active IP Right Cessation
- 2007-06-15 WO PCT/EP2007/005303 patent/WO2007147529A2/en active Application Filing
- 2007-06-15 CN CNA2007800232312A patent/CN101472610A/en active Pending
- 2007-06-15 EP EP07764675A patent/EP2029169A2/en not_active Withdrawn
- 2007-06-15 JP JP2009515748A patent/JP2009541236A/en not_active Ceased
- 2007-06-15 MX MX2008016036A patent/MX2008016036A/en active IP Right Grant
- 2007-06-15 KR KR1020087030973A patent/KR101141333B1/en not_active IP Right Cessation
- 2007-06-15 RU RU2009101387/15A patent/RU2453335C2/en not_active IP Right Cessation
- 2007-06-15 US US12/306,227 patent/US20100129403A1/en not_active Abandoned
-
2008
- 2008-12-03 IL IL195683A patent/IL195683A0/en unknown
-
2009
- 2009-01-09 MA MA31557A patent/MA30581B1/en unknown
- 2009-01-13 NO NO20090194A patent/NO20090194L/en not_active Application Discontinuation
- 2009-01-16 CR CR10571A patent/CR10571A/en not_active Application Discontinuation
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4689338A (en) | 1983-11-18 | 1987-08-25 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
EP0385630A2 (en) | 1989-02-27 | 1990-09-05 | Riker Laboratories, Inc. | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
WO1992015672A1 (en) | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
WO1994017043A1 (en) | 1993-01-29 | 1994-08-04 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
WO1995027780A1 (en) | 1994-04-06 | 1995-10-19 | Virogenetics Corporation | Poxvirus-canine distemper virus (cdv) recombinants and compositions and methods employing the recombinants |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
WO2002024225A1 (en) | 2000-09-20 | 2002-03-28 | Glaxo Group Limited | Use of immidazoquinolinamines as adjuvants in dna vaccination |
US20040076633A1 (en) | 2000-09-20 | 2004-04-22 | Thomsen Lindy Loise | Use of immidazoquinolinamines as adjuvants in dna vaccination |
US6913752B2 (en) | 2000-11-23 | 2005-07-05 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant |
US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
WO2003080114A2 (en) | 2002-03-19 | 2003-10-02 | Powdermed Limited | Imidazoquinoline adjuvants for vaccines |
WO2005018574A2 (en) | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
WO2006042254A2 (en) | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
Non-Patent Citations (20)
Title |
---|
BUCK, INFECT. DIS. OBSTET. GYNECOL., vol. 6, 1998, pages 49 - 51 |
COX ET AL.: "Viruses in Human Gene Therapy", ACADEMIC PRESS |
DOCKRELL; KINGHORN, J. ANTIMICROB. CHEMOTHER, vol. 48, 2001, pages 751 - 755 |
DOCKRELL; KINGHORN, J. ANTIMICROB. CHEMOTHER., vol. 48, 2001, pages 751 - 755 |
FAYNSOD ET AL., ANNALS OF SURGICAL ONCOLOGY, vol. 11, 2004, pages 570 |
GARLAND, CURR. OPIN. INFECT. DIS., vol. 16, 2003, pages 85 - 89 |
GOEBEL ET AL., VIROL., vol. 179, 1990, pages 247 - 266,517-563 |
JOHNSON ET AL., VIROL., vol. 196, 1993, pages 381 - 401 |
JONES, CURR. OPIN. INVESTIG. DRUGS., vol. 4, 2003, pages 214 - 218 |
KAUFMAN, ANN. N.Y. ACAD. SCI., vol. 1062, 2005, pages 41 - 50 |
LIU ET AL., PROC. NAT. ACAD SCI, vol. 101, no. 2, 2004, pages 14567 - 14571 |
MAYR, A. ET AL., INFECTION, vol. 3, 1975, pages 6 - 14 |
PAOLETTI ET AL., DEV BIOL STAND., vol. 84, 1995, pages 159 - 163 |
PEREZ; BRADY: "Principles and Practice of Radiation Oncology", 1992, JB LIPPINCOTT CO |
REYES-SANDOVAL; ERTL, CURRENT MOLECULAR MEDICINE, vol. 1, 2001, pages 217 - 243 |
See also references of EP2029169A2 |
SMORLESI ET AL., GENE THERAPY, vol. 12, 2005, pages 1324 - 1332 |
TARTAGLIA ET AL., VIROLOGY, vol. 188, 1992, pages 217 - 232 |
VASILAKOS ET AL., CELLULAR IMMUNOLOGY, vol. 204, no. 1, 2000, pages 64 - 74 |
ZUBER ET AL., VACCINE, vol. 22, 2004, pages 1791 - 1798 |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011015656A3 (en) * | 2009-08-07 | 2011-03-31 | Transgene Sa | Composition for treating hbv infection |
US9393299B2 (en) | 2009-08-07 | 2016-07-19 | Transgene S.A. | Composition for treating HBV infection |
WO2011015656A2 (en) | 2009-08-07 | 2011-02-10 | Transgene Sa | Composition for treating hbv infection |
WO2013007772A1 (en) | 2011-07-12 | 2013-01-17 | Transgene Sa | Hbv polymerase mutants |
WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
WO2014009438A2 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
WO2015104380A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
EP3552615A1 (en) | 2014-07-16 | 2019-10-16 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
WO2018122088A1 (en) | 2016-12-28 | 2018-07-05 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | Oncolytic viruses expressing agents targeting metabolic immune modulators |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
WO2021040056A1 (en) | 2019-08-29 | 2021-03-04 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
KR20230038496A (en) | 2020-07-13 | 2023-03-20 | 트랜스진 | treatment of immunosuppression |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Also Published As
Publication number | Publication date |
---|---|
CN101472610A (en) | 2009-07-01 |
CA2656266A1 (en) | 2007-12-27 |
NO20090194L (en) | 2009-03-10 |
AU2007263281A1 (en) | 2007-12-27 |
JP2009541236A (en) | 2009-11-26 |
AU2007263281B2 (en) | 2012-12-06 |
WO2007147529A3 (en) | 2008-02-28 |
MX2008016036A (en) | 2009-04-07 |
RU2009101387A (en) | 2010-07-27 |
MA30581B1 (en) | 2009-07-01 |
BRPI0713711A2 (en) | 2012-10-30 |
KR20090016719A (en) | 2009-02-17 |
IL195683A0 (en) | 2011-08-01 |
CA2656266C (en) | 2012-07-31 |
RU2453335C2 (en) | 2012-06-20 |
CR10571A (en) | 2009-05-14 |
KR101141333B1 (en) | 2012-05-23 |
US20100129403A1 (en) | 2010-05-27 |
EP2029169A2 (en) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2656266C (en) | Recombinant viral vaccine | |
US9261512B2 (en) | Biomarker for treating cancer patients | |
US9207231B2 (en) | Biomarker for selecting patients and related methods | |
KR20120027146A (en) | Biomarker for monitoring patients | |
US20100150969A1 (en) | immune response | |
KR20110138354A (en) | Biomarker for monitoring patients | |
WO2008046576A1 (en) | Use of glucocorticoid antagonists in vaccination | |
EP2387414A1 (en) | Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780023231.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07764675 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007263281 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 195683 Country of ref document: IL Ref document number: 573362 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007764675 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008502733 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6812/CHENP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2008/016036 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2656266 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08134829 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009515748 Country of ref document: JP Ref document number: 1020087030973 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008122037 Country of ref document: EG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007263281 Country of ref document: AU Date of ref document: 20070615 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2009-010571 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2009101387 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12306227 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0713711 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081217 |